Welcome listeners to our fifth episode of our second season, that will delve into the complex realm of global clinical trials and the access Asian patients actually have had in novel/innovative treatments – quite probably one of the most inequitable of standards in healthcare and one that hasn’t been understood deeply enough. We’re a group of like-minded health editors, researchers and writers who’ve spent a career in trying to track the evolution of healthcare in parts of the developing world, particularly Asia-Pacific. So essentially this is a neutral, independent non-profit platform that aims to produce deep insights and knowledge on public health issues in Asia Pacific, rooted in local circumstances, experiences, and divergences.

We'll be joined today by two stalwarts of the oncology and clinical trial world, one who has represented the path that clinical research and trials have had to traverse in Asia and the other who is now trailblazing the future of technology-enabled patient outcomes.

Jean Paul Deslypere, Founder & CEO of Aesculape, a Singapore-based Clinical Research Organisation, with offices in 9 countries and more than 30 professionals worldwide and applies therapeutic experience and expertise to help customers and partners bend the cost and time curve of drug development.

Dr Huren Sivaraj, Co-Founder and CEO Oncoshot, a really unique startup that help patients, caregivers, and oncologists identify clinical trials more efficiently and effectively in today’s fast-changing landscape of cancer care. Their platform generates leads for relevant clinical trials in minutes, whereas with the traditional approach it can take weeks.